FRACTION-RCC: A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology agents in patients with advanced RCC Meeting Abstract
| Authors: | Taitt, C. C.; Motzer, R. J.; Choueiri, T. K.; Escudier, B. J.; Kuzel, T.; Carducci, M. A.; Nair, S.; Tykodi, S. S.; Tannenbaum-Dvir, S.; Wind-Rotolo, M.; Simonsen, K. L.; Fracasso, P. M. |
| Abstract Title: | FRACTION-RCC: A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology agents in patients with advanced RCC |
| Meeting Title: | 32nd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 5 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Nov 8-12 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2017-11-07 |
| Start Page: | 87 |
| Language: | English |
| DOI: | 10.1186/s40425-017-0288-4 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: P226 |
